{
    "clinical_study": {
        "@rank": "89031", 
        "arm_group": [
            {
                "arm_group_label": "conventional ovarian stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment"
            }, 
            {
                "arm_group_label": "individualized ovarian stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "women whose protocol of ovarian stimulation was based on anti-mullerian hormone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose oh the study is to determine the usefulness of anti-Mullerian hormone (AMH) to\n      identify women at risk of excessive and poor response in controlled ovarian stimulation\n      (COS) for in vitro fertilization (IVF), and the clinical impact of applying individualized\n      COS strategies in these subsets of patients."
        }, 
        "brief_title": "Individualization of Controlled Ovarian Stimulation Using Anti-mullerian Hormone as a Biomarker of Ovarian Response Maximize the Beneficial Effects of Treatment and Minimize Complication and Risk.", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "A group of 130 women undergoing conventional COS after pituitary down-regulation for IVF\n      will be  studied to determine the best cut-off points of AMH, using receiver operating\n      characteristic (ROC) analysis, to discriminate excessive (\u226520 oocytes retrieved) and poor\n      response (\u22644 oocytes retrieved). The inclusion criteria is any patient with indication of\n      IVF treatment. Subsequently, a different group of 120 women (with the same criteria) will be\n      assessed using AMH before starting COS, and treatment strategy will be individualized\n      according to AMH results (iCOS). Mild stimulation using daily doses (112.5 to 150 IU) of\n      recombinant follicle stimulation hormone (rec-hFSH) or rec-hFSH combined with recombinant\n      luteinizing hormone (LH) supplementation (375 IU total daily dose) will be given to patients\n      identified as at risk of excessive and poor response, respectively. It will evaluated:\n      number of oocytes, clinical pregnancy rates (defined as fetal heartbeat on ultrasound\n      performed 4 weeks after the transfer of embryos) and occurrence of Ovarian hyperstimulation\n      syndrome). Outcomes will be compared between the groups who received conventional and iCOS\n      using chi-square and Fisher exact tests."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women with in vitro fertilization treatment indication\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887652", 
            "org_study_id": "ANDRO-03-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "conventional ovarian stimulation", 
                "description": "a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.", 
                "intervention_name": "conventional ovarian stimulation", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "individualized ovarian stimulation", 
                "description": "After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (\u226520 oocytes retrieved) and poor response (\u22644 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.", 
                "intervention_name": "individualized ovarian stimulation", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "In Vitro Fertilization", 
            "ovulation induction", 
            "anti-mullerian hormone"
        ], 
        "lastchanged_date": "June 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Campinas", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13075-460"
                }, 
                "name": "Androfert"
            }, 
            "investigator": [
                {
                    "last_name": "Rogerio BF Leao, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sandro C Esteves, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fabiana Y Nakano, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Individualization of Controlled Ovarian Stimulation Using Anti-mullerian Hormone as a Biomarker of Ovarian Response Maximize the Beneficial Effects of Treatment and Minimize Complication and Risk.", 
        "overall_contact": {
            "email": "rogerioleao@androfert.com.br", 
            "last_name": "Rogerio BF Leao, MD", 
            "phone": "+5511960677676"
        }, 
        "overall_contact_backup": {
            "email": "s.esteves@androfert.com.br", 
            "last_name": "Sandro C Esteves, PhD", 
            "phone": "+55193295-8877"
        }, 
        "overall_official": [
            {
                "affiliation": "ANDROFERT - Clinica de Andrologia e Reproducao Humana", 
                "last_name": "Rogerio BF Leao, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ANDROFERT - Clinica de Andrologia e Reproducao Humana", 
                "last_name": "Sandro C Esteves, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "ANDROFERT - Clinica de Andrologia e Reproducao Humana", 
                "last_name": "Fabiana Y Nakano", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "number of oocyte retrieved classified as: poor response: \u22644 oocytes normal response: 5 - 19 oocytes excessive response: \u226520 oocytes", 
            "measure": "number of oocytes retrieved", 
            "safety_issue": "No", 
            "time_frame": "1 day (on the day of oocyte retrieval)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "presence of fetal heartbeat on transvaginal ultrasound", 
                "measure": "clinical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after embryo transfer"
            }, 
            {
                "description": "presence of hyperstimulation syndrome during follow up after oocyte retrieval", 
                "measure": "occurrence of ovarian hyperstimulation syndrome", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks after embryo transfer"
            }, 
            {
                "description": "cancellation of the cycle because of no ovarian response (no follicles >14 mm during ovarian stimulation)", 
                "measure": "cancellation", 
                "safety_issue": "No", 
                "time_frame": "on the 8th day of ovarian stimulation"
            }
        ], 
        "source": "ANDROFERT - Clinica de Andrologia e Reproducao Humana", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ANDROFERT - Clinica de Andrologia e Reproducao Humana", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}